Fiche centre
Cancer Institute Hospital of JFCR ( Site 3404)
Koto — Japan
Essais liés2clinical trials
VilleKotolocalisation
PaysJapanlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06170788
Essais cliniques associés
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Pembrolizumab | Cancer | Phase 3 | NCT06393374 | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | RECRUITING |
| Sacituzumab Tirumotecan | Parkinson | Phase 3 | NCT06170788 | TroFuse-007 — Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) | RECRUITING |